Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Finished Goods (2023 - 2025)

Tarsus Pharmaceuticals has reported Finished Goods over the past 3 years, most recently at $3.0 million for Q4 2025.

  • Quarterly results put Finished Goods at $3.0 million for Q4 2025, up 47.66% from a year ago — trailing twelve months through Dec 2025 was $3.0 million (up 47.66% YoY), and the annual figure for FY2025 was $3.0 million, up 47.66%.
  • Finished Goods for Q4 2025 was $3.0 million at Tarsus Pharmaceuticals, up from $2.8 million in the prior quarter.
  • Over the last five years, Finished Goods for TARS hit a ceiling of $3.0 million in Q4 2025 and a floor of $182000.0 in Q4 2023.
  • Median Finished Goods over the past 3 years was $1.9 million (2025), compared with a mean of $1.7 million.
  • Biggest five-year swings in Finished Goods: surged 1002.2% in 2024 and later skyrocketed 47.66% in 2025.
  • Tarsus Pharmaceuticals' Finished Goods stood at $182000.0 in 2023, then surged by 1002.2% to $2.0 million in 2024, then surged by 47.66% to $3.0 million in 2025.
  • The last three reported values for Finished Goods were $3.0 million (Q4 2025), $2.8 million (Q3 2025), and $2.3 million (Q2 2025) per Business Quant data.